Ophthalmology

Raymond Douglas, MD, PhD, discusses data that demonstrate the benefit of teprotumumab in patients with all levels of thyroid eye disease.

Edmund Tsui, MD, talks the new AAO 2020 virtual format as well as presentations that have particularly caught his attention.

There was a substantial increase in drug use-related endogenous endophthalmitis hospitalizations between 2003 and 2016.

A new health care pathway could be safe to implement in clinical practice.

A younger baseline age and more injections during the first year of treatment was linked to better long-term outcomes.

A large population study in Taiwan found regular use of aspirin for prevention of cardiac events increased risk for age-related macular degeneration.

A daily drop of oxymetazoline ophthalmic could avert surgery for acquired ptosis, according to new findings.

Cataracts, but not AMD or glaucoma, were associated with an increased risk of depressive symptoms in the elderly in a prospective long-term study.

Pupillary light reflex metrics could provide an objective biomarker to determine whether an adolescent athlete has suffered a concussion.

SFChT in treatment-naïve eyes was positively associated with eGFR and diabetic retinopathy grade.

Ketotifen fumarate ophthalmic solution 0.035% is the first and only over-the-counter preservative-free eye drop solution for itchy eyes caused by allergies.

According to a retrospective claims database study, as many as 43.8% of assessed patients with open-angle glaucoma required a change from initial treatment.

Dr. Mali talks about advancements in treatment and screening for Wet AMD.

More than half of the eyes observed in the study displayed collapse of the associated druse or drusenoid PED.

At recommended adherence rates, automatic AI screening technology for diabetic retinopathy is a preferred strategy over conventional eye care professional screening.

The role of telehealth and teleophthalmology can continue to expand even after COVID-19.

More than 20% of children examined in Wuhan showed various ocular manifestations.

A phase 2 trial will begin to evaluate the safety and efficacy of RGX-314.

This is the first and only FDA-approved cysteamine eye drop formulation, which is self-applied 4 times daily during waking hours.

A new survey assessed patients’ confidence in their disease management during the pandemic, specific disease management concerns, and experiences with telemedicine.

The risk of developing fibrosis and macular atrophy increased based on which quartile of foveal center point thickness standard deviation an individual falls in.

Over a nine-year period, the observed incidence of ROP in infants with very low birth weight was 317.14 per 1000 newborns.

A single nucleotide polymorphism is associated with severe and proliferative retinopathy risk reduction by 42% and 63%, respectively.

The degree of photoreceptor degeneration outside of regions of retinal pigment epithelium atrophy varied substantially between eyes with AMD.

REGENXBIO also announced the scheduling of a phase 2 trial testing RGX-314 for wet AMD.